Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2007, the company has established itself as a leader in developing innovative injectable products, particularly in the areas of oncology and critical care. With a focus on improving patient outcomes, Eagle Pharmaceuticals offers unique formulations that enhance the delivery and efficacy of established therapies. The company has achieved significant milestones, including the successful launch of its flagship product, Ryanodex, which is designed for the treatment of malignant hyperthermia. Eagle's commitment to quality and innovation has positioned it favourably in a competitive market, earning recognition for its contributions to patient care and drug accessibility. With operations extending across major regions in the US, Eagle Pharmaceuticals continues to drive advancements in the biopharmaceutical landscape.
DitchCarbon Score
How does Eagle Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eagle Pharmaceuticals, Inc.'s score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eagle Pharmaceuticals, Inc.'s reported carbon emissions
Eagle Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Eagle Pharmaceuticals has not inherited any emissions data from a parent or related organization, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) that would provide a framework for emissions reduction. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate commitments. However, without specific data or targets, it is unclear how Eagle Pharmaceuticals aligns with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eagle Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
